LENGTH OF STAY AND ANTIPSYCHOTIC TREATMENT COSTS OF PATIENTS WITH ACUTE PSYCHOSIS ADMITTED TO HOSPITAL- DESCRIPTION AND ASSOCIATED FACTORS – THE PSYCHOSP STUDY
Author(s)
Peiró S1, Gómez G2, Navarro M3, Guadarrama I4, Rejas J5, 1Fundación Instituto de Investigación en Servicios de Salud, Escuela Valenciana de Estudios para la Salud, Valencia, Spain; 2Fundación Instituto de Investigación en Servicios de Salud, Valencia, Spain; 3Servicio de Farmacia, Hospital de Santa Maria, Lleida, Spain; 4División Corporativa e Institucional, Pfizer SA, Alcobendas, Madrid, Spain; 5Pfizer, S.A, Alcobendas, Madrid, Spain
OBJECTIVE: To describe the length of stay, cost of drug treatment, diagnostic tests and other therapeutic measures in acute psychotic patients admitted to acute in-patient psychiatric units and to analyse the factors associated with these. METHODS: Retrospective review of medical records of 200 patients admitted for acute psychosis in 8 Spanish hospitals. Description of the length of stay, cost of drug treatment and diagnostic tests; bivariate and multivariate analysis of factors associated with length of stay and cost of antipsychotic drug treatment. RESULTS: The average admission cost ranged between €2,830.29 and €3,624.95, with a wide variability among hospitals. Of this cost, 94.3% corresponded to fixed costs, 3.4% to diagnostic tests and 2.4% to drug treatment (84.2% of this latter cost corresponded to antipsychotic drugs). An age younger than 25 years and a diagnosis of schizophrenia were associated with longer hospital stays; longer length of stay, the presence of aggressiveness/agitation, a diagnosis of schizophrenia, age younger than 25 years and the use of atypical antipsychotics were associated with higher costs in antipsychotic drug treatment. CONCLUSIONS: The hospital admission cost of an acute psychotic episode is mostly dependent on the structural costs derived from in-patient treatment. The differences in costs seem to be related to different length of stay schemes used by the various hospitals rather than to the clinical characteristics of patients or the drugs used.
Conference/Value in Health Info
2002-11, ISPOR Europe 2002, Rotterdam, The Netherlands
Value in Health, Vol. 5, No. 6 (November/December 2002)
Code
PMH10
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Mental Health